一例醋酸阿比特龙撤药病例。 - Suppr

A case of abiraterone acetate withdrawal.

作者信息

Witjes J Alfred

出版信息

Eur Urol. 2013 Sep;64(3):517-8. doi: 10.1016/j.eururo.2013.06.013. Epub 2013 Jun 19.

DOI:10.1016/j.eururo.2013.06.013

PMID:23806520

Abstract

摘要

相似文献

A case of abiraterone acetate withdrawal.

Eur Urol. 2013 Sep;64(3):517-8. doi: 10.1016/j.eururo.2013.06.013. Epub 2013 Jun 19.

Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8.

Eur Urol. 2014 Jan;65(1):e10-1. doi: 10.1016/j.eururo.2013.08.035. Epub 2013 Aug 26.

Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur Urol 2013;64:517-8.

Eur Urol. 2014 Apr;65(4):e54-5. doi: 10.1016/j.eururo.2013.11.038. Epub 2013 Dec 11.

Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.

Clin Cancer Res. 2017 Feb 1;23(3):726-734. doi: 10.1158/1078-0432.CCR-16-1070. Epub 2016 Aug 3.

Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?

Eur Urol. 2014 Feb;65(2):504-5. doi: 10.1016/j.eururo.2013.10.035. Epub 2013 Nov 1.

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

Eur Urol. 2013 Jan;63(1):111-20. doi: 10.1016/j.eururo.2012.07.040. Epub 2012 Jul 27.

Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.

Cancer. 2013 Sep 1;119(17):3103-4. doi: 10.1002/cncr.28314.

Prostate cancer: The androgen receptor remains front and centre.

Nat Rev Clin Oncol. 2013 Mar;10(3):126-8. doi: 10.1038/nrclinonc.2013.14. Epub 2013 Feb 5.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

[Antiandrogen withdrawal syndrome].

Nihon Rinsho. 1998 Aug;56(8):2135-9.

引用本文的文献

Androgen Receptor Signaling Inhibitor Withdrawal Syndrome After Castration-resistant Prostate Cancer.

Cancer Diagn Progn. 2024 Nov 3;4(6):684-688. doi: 10.21873/cdp.10382. eCollection 2024 Nov-Dec.

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high-risk prostate cancer.

IJU Case Rep. 2023 Jul 21;6(5):282-285. doi: 10.1002/iju5.12604. eCollection 2023 Sep.

Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.

Oncol Lett. 2018 Feb;15(2):2669-2672. doi: 10.3892/ol.2017.7628. Epub 2017 Dec 14.

[Antihormonal therapy in prostate cancer : Side effects].

Urologe A. 2017 Apr;56(4):465-471. doi: 10.1007/s00120-017-0340-5.

Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.

J Manag Care Spec Pharm. 2017 Feb;23(2):225-235. doi: 10.18553/jmcp.2016.16233. Epub 2016 Dec 7.

Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC).

Springerplus. 2014 Oct 1;3:574. doi: 10.1186/2193-1801-3-574. eCollection 2014.

Abiraterone in the treatment of metastatic castration-resistant prostate cancer.

Cancer Manag Res. 2014 Jan 28;6:39-51. doi: 10.2147/CMAR.S39318. eCollection 2014.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A case of abiraterone acetate withdrawal.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献